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A formal goal of gene expression studies in cancer is to
reconstruct the pathways that characterize tumor behavior
through its transcriptional signature (Liu, 2005; Liu et al,
2006). The ultimate utility is not only to discover molecular
components of these cancers, but also to exploit this knowl-
edgetoimprovetherapeutics(Bildetal,2006a).Toaccomplish
this,a numberof approacheshave beenused toachievehigher
level order in the expression of gene sets (Mootha et al, 2003;
Segal et al, 2004; Subramanian et al, 2005; Bild et al, 2006b).
Recently, Tomlins et al (2007) made a further contribution to
this effort by devising an approach to construct a molecular
concept map (MCM) in the analysis of human prostate
cancers. In this work, theymicrodissected101 prostate cancers
that ranged from benign epithelium to metastatic disease and
assessed the expression of transcripts on a genome-wide scale
using printed cDNA microarrays. Approximately 14000
molecular ‘concepts’ representing biologically connected
genes were used to analyze the expression proﬁles and
identify a number of relevant pathways that might drive
prostate cancer biology.
As in many good scientiﬁc articles, several layers of
importance that are signiﬁcant to different research commu-
nities can be found. Pertinent to this journal, this paper by
Tomlins et al (2007) provides an instructive focal point for the
discussion of fundamental problems that bedeviled systems
biologists working on primary human cancers. For example,
given the complexity of mammalian systems and the further
geneticscramblingthattakesplacewithcancer,isitpossibleto
develop systems approaches that can solidly map, in cancer
cells, interactions relevant to clinical cancer biology? Does
MCM provide deﬁnitive answers to these problems? The
honest answer must be no, but Tomlins et al (2007) do lay out
solid ideas as to the direction of future work in systems
medicine.
The primary contribution is the application of the MCM
approach.‘Molecular concepts’ are sets of genes related in a
biologically meaningful way, but these concepts may reside in
different planes of association. The molecular concepts that
populate an MCM come in three forms that are heterogeneous
in character: (1) gene and protein annotations from external
databases (including from cell lines as well as primary
cancers), (2) computationally derived regulatory networks
and (3) microarray gene expression proﬁles. The external
annotation included chromosomal locations, protein domains
and families, molecular functions, cellular localizations,
biological processes, signaling and metabolic pathways,
protein–protein interaction networks and protein complexes.
Presumablyanyelements that areconsistentlyassociated with
each other would be candidates. The strength of such an
approach is that it takes into account all available knowledge
of genetic relationships pertinent to prostate cancer, and
knowledgethat isnotrestrictedto onlyone technicalplatform.
Expression signatures resulting from the proﬁling of
prostate cancer samples are then analyzed using this large
collection of molecular concepts. More precisely, pairs of
concepts are tested for signiﬁcant association as indicated
by enrichment and disproportionate overlap of the respective
gene sets within the top-ranking genes in the expression
signature. In this way, a map of connected concepts, the MCM,
is constructed, which delineates the landscape of interlinked
biological events and processes that underlie the expression
signature analyzed.
The conceptual approach of deconvolving microarray
expression proﬁles using predeﬁned gene sets that integrate
heterogeneous biological knowledge is not completely new
and has been described by other groups and applied to human
disease in approaches bearing related names such as ‘gene set
enrichment analysis (GSEA)’ (Mootha et al, 2003; Subrama-
nian et al, 2005),‘gene module maps’ (Segal et al, 2004) and
‘pathway signatures’ (Bild et al, 2006b). The GSEA technique
was initially applied to identify genes deregulated in human
diabetic muscle (Mootha et al, 2003). Screening of 150 gene
sets, among which are most of the classical metabolic
pathways, led to the identiﬁcation of a set of PGC1a-regulated
genes involved in oxidative phosphorylation. In their ‘module
map’ approach, Segal et al (2004) used almost 3000 gene sets
to analyze a compendium of cancer-related microarray data
sets (Segal et al, 2004). After simplifying the overlaps between
gene sets, 400 modules were extracted, and combinatorial
activation or deactivation of these can be followed in clinical
samples to identify, for example, core processes common to
heterogeneous tumor types. Building as this concept of
reconstructing pathway-based systems maps, Bild et al
(2006b) mapped multiple oncogenic pathway expression
signatures from human cell line models using transgenic
mouse mammary tumor models for validation and regressed
the data into pathway activity scores. When applied to human
tumors of different types, the pathway activity scores were
able to classify tumors into groups associated with disease
recurrence.Moreover,thepathwayactivitysignaturescouldbe
used to predict the response of cell lines to drugs known to
target speciﬁc components of the given oncogenic pathways.
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of transcriptional signatures predictive of therapeutic outcome
in patients (Potti et al, 2006).
Common to these various approaches are the detection of
coordinate changes of groups of genes, pre-deﬁned as
biologically related either experimentally or by data and
literature mining. These techniques therefore go beyond a
gene-by-gene analysis and are usually more sensitive in
detecting modest changes in expression levels, which makes
them particularly powerful for the analysis of human clinical
samples.In addition, thefact that biologicallyand functionally
relatedgenesaretestedcollectivelyprovidesadirectbiological
interpretation to the analysis. Compared to the techniques
described above, the main aspect of novelty of the MCM
approach are the impressive size of the gene set collection
(more than 14000), which enables the exploration of a myriad
of biological functions, and the fact that pairwise association
of concepts are identiﬁed rather than simply ranking indivi-
dual candidate pathways. Here, the MCM provides, in
principle, a more integrated view of the network of biological
processes that are active under a given physiological setting
and, therefore, facilitate the interpretation of microarray
expression signatures.
Although the above methodologies are efﬁcient in uncover-
ing groups of coordinately regulated genes, follow-up studies
still face the challenge of identifying the molecular mechan-
isms responsible for the co-regulation of the identiﬁed path-
ways/concepts/modules. Chang et al (2005) attacked the
problem in mammalian cancers in a series of publications.
First, they extracted gene expression modules from expression
arrays of primary breast cancers and derived the expression
signatures of speciﬁc physiologic mechanisms pertinent to the
disease: wound healing and serum response of cultured
ﬁbroblasts. By removing the cell-cycle-associated genes, they
settled on 512 core serum response (CSR) genes that were
considered representative of a ‘wound’ signature and found a
strong correlation with survival. Integrating gene ampliﬁca-
tion and gene expression information, they later discovered
that this wound signature is activated by coordinate ampliﬁca-
tion of CSN5, an activator of cullin-based E3 ubiquitin ligases,
and the oncogenic transcription factor MYC (Adleret al, 2006).
Taken together, their map of the transcriptional control
network for the wound response in a complex system like
human breast cancer revealed that the induction of a
transcriptional wound response (CSR) requires not one but
two genetic elements, MYC and CSN5, to be activated. Using
a systems approach, these investigators identiﬁed components
that provide a synthetic or conditional effect.
The work by Tomlins et al (2007) and works by the others
mentioned in this article show that such systems maps can be
applied in complex mammalian systems and yield results that
canprovideinsightintohumanrelevantdiseases.Tomlinsetal
(2007) included a few more incremental innovations in
experimentation design for studies focused on network maps
in cancer. First, the authors heroically microdissected 101
prostate cancers for analysis to eliminate variable and
confounding signals from non-malignant stromal tissues. In
most expression signature studies of primary tumors, whole
tissues rather than dissected tissues are used and have
generated clinically important data. They correctly point out
that if prognosis is the sole goal, then the stromal signals
contribute to patient outcome predictions. In this case, the
stromal signals are greater in localized disease and less in the
disease with metastatic potential. However, if a map of
the intracellular network of a prostate cancer cell is the goal,
then elimination of the stromal signal is important.
The outcome of their analysis of the clustering of the
expressionsignaturesisalsointeresting.Intermsofexpression
architecture, the expression concepts show similarity between
PIN (averyearly form of prostate cancer) and prostate cancers
both of which differ from benign prostatic tissue. This is also
what has been described for breast cancer, where the
expression signature of DCIS (ductal carcinoma in situ,a
preinvasive lesion) is similar to invasive cancer. This suggests
that at least in some common epithelial cancers, the majority
of the molecular changes in a cancer cell has already taken
place in the earliest forms of the cancer. More speciﬁcally, the
transition from benign to localized prostate cancer to meta-
static disease is accompanied by an increase in expression of
protein synthesis and proliferation concepts, by a decrease in
androgen effects and by an increase in concepts related to the
activity of the ETS family of transcription factors. This last
result was important in view of the recent discovery of
TMRPSS2:ETS gene fusions in the majority of prostate cancers
(Tomlins et al, 2005), suggesting that ETS transcription factors
may play a key role in prostate cancer progression.
Certainly, the most elegant systems network studies have
been conducted in lower organisms such as bacteria, yeast
or the sea urchin for obvious reasons. The simplicity of the
systems, the ability to control experimental conditions and the
knowledge base of how these organisms behave to speciﬁc
stimuli all provide the precise high content data needed to
render good dynamic interaction maps. However, the work
reviewed herein, all focused on human cancers, show that
some of these lessons learned in lower organisms can be
applied to human tissues. Importantly, the information
generated in this fashion are clinically relevant. Perhaps
systems medicine is ﬁnally coming of age.
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